BMC Endocrine Disorders is calling for submissions to our Collection, Incretin-based therapies for cardiometabolic disease: mechanisms and clinical outcome.

Incretin-based therapies, particularly glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dual GLP-1/ Glucose-dependent Insulinotropic Polypeptide (GIP) receptor agonists have emerged as pivotal treatments in managing type 2 diabetes (T2D) and its associated cardiometabolic complications. These therapies leverage the physiological effects of endogenous incretins, modulating insulin and glucagon secretion and promoting satiety and contributing to superior glycemic control and weight management. As the prevalence of T2D and atherosclerotic cardiovascular disease (ASCVD) continues to rise globally, understanding the underlying mechanisms and clinical outcomes of these therapies is crucial for optimizing patient care.

Research in incretin-based therapies has made significant strides, demonstrating not only their effectiveness in lowering hemoglobin A1c (HbA1c), but also expanding more broadly into cardiovascular and metabolic benefits. Recent studies have revealed that GLP-1 RAs can reduce the risk of major cardiovascular events in higher risk populations, highlighting their role beyond traditional glucose control. Additionally, ongoing investigations into the molecular mechanisms of action may provide insights into novel therapeutic targets and inform personalized treatment strategies, ultimately improving patient outcomes in cardiometabolic disease.

As research in incretin-based therapies progresses, with further novel drugs in development leveraging GLP-1 as a backbone, we can anticipate further advancements that may enhance their efficacy and broaden their applications. Future studies may uncover new combinations of incretin therapies with other treatment modalities, providing synergistic effects for glycemic control and cardiovascular health. Moreover, a deeper understanding of patient-specific responses may lead to tailored therapies that maximize benefits while minimizing adverse effects, thereby revolutionizing the management of type 2 diabetes and its complications.

Topics may include, but are not limited to:

• Effects of GLP-1 RAs on cardiovascular and broader metabolic outcomes
• Comparative efficacy of GLP-1 RA and dual GLP-1/ GIP RAs
• Mechanisms underlying incretin therapy benefits
• Role of incretin therapy in weight management

This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.

This is a Sister Collection with Cardiovascular Diabetology.

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer-review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.

BMC Endocrine Disorders is calling for submissions to our Collection, Diabetes in older adults.

The prevalence of diabetes among the elderly population is rapidly increasing, creating a pressing public health concern that warrants extensive research and understanding. As individuals age, physiological changes, including alterations in insulin sensitivity and the presence of comorbidities, complicate diabetes management. Furthermore, the heterogeneous nature of diabetes in older adults often leads to underdiagnosis or misdiagnosis, emphasizing the need for focused research on this demographic. This Collection invites contributions that delve into the various aspects of diabetes in older age, encompassing its pathophysiology, management strategies, and the unique challenges faced by elderly patients.

Understanding diabetes in the elderly is crucial for developing effective treatment protocols and improving quality of life for this vulnerable group. Recent advancements in geriatric care and diabetes management have highlighted the importance of personalized medicine, integrating technology and patient-centered approaches. Research has shown that tailored interventions can significantly enhance glycemic control while minimizing adverse effects, leading to better health outcomes. As the aging population continues to grow, it is imperative that we expand our knowledge base and refine care strategies to meet the needs of elderly individuals with diabetes.

Continued research in this area may lead to groundbreaking advances in the management of diabetes in older adults, including the development of innovative therapies and technologies that cater specifically to their needs. Enhanced understanding of the interplay between aging, diabetes, and comorbidities may also foster more effective strategies for prevention and early intervention. Ultimately, ongoing efforts can pave the way for improved health outcomes and enhanced quality of life for the elderly living with diabetes.

Topics that are welcome include, but are not limited to, the following:

Management strategies for diabetes in older adults

Insulin resistance and aging

Geriatric care approaches for diabetes

Diabetes-related morbidity in the elderly

Evidence-based nutritional therapy

Exercise therapy

This Collection supports and amplifies research related to SDG 3: Good Health & Well-being

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer-review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.